Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : AVC-101,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Novo Holdings
Deal Size : $112.0 million
Deal Type : Series B Financing
AvenCell Raises $112 Million in Series B; Funding Led by Novo Holdings
Details : The proceeds will accelerate AvenCell's proprietary Universal Switchable CAR-T cell therapy platform, including AVC-101, for a wide range of hematologic malignancies and auto-immune diseases.
Brand Name : AVC-101
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
October 22, 2024
Lead Product(s) : AVC-101,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Novo Holdings
Deal Size : $112.0 million
Deal Type : Series B Financing
Details : AVC-101 is a CD-123-directed cell therapy targeting acute myeloid leukemia, that utilizes AvenCell’s proprietary Universal Targeting platform, a regulatable CAR T cell technology that can turn CAR T cells “OFF” and “ON” by means of separately i...
Brand Name : AVC-101
Molecule Type : Large molecule
Upfront Cash : Not Applicable
November 03, 2022
LOOKING FOR A SUPPLIER?
Reset All
